Search Results

Glythera Announces Corporate Name Change and Rebranding to Iksuda Therapeutics

Glythera Limited (Glythera), the next-generation Antibody Drug Conjugate (ADC) development company, today announced that it has changed its name to Iksuda Therapeutics (Iksuda) and unveiled a new corporate brand.

September 10, 2018

·

1 min read

Business

Glythera Appoints Chief Scientific Officer and Strengthens SAB

Dr Lutz will lead the advancement of Glythera’s portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers.

January 17, 2018

·

2 min read

Business

Glythera Appoints Professor Kerry Chester to SAB

Glythera Limited announces that it has appointed Professor Kerry Chester to its Scientific Advisory Board (SAB).

April 30, 2018

·

1 min read

Business

Avacta Group Plc Announces Positive Outcome of Proof-of-Concept Study With Glythera and Follow-on Drug Development Partnership

Avacta Group plc is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully.

January 15, 2018

·

2 min read

Business

Glythera Licenses Novel Payload Class

September 27, 2017

·

5 min read

Business

Glythera And IONTAS Enter Into License Agreement For The Development Of Multiple Antibodies For Next-Generation Antibody Drug Conjugates

September 20, 2017

·

2 min read

Business

Glythera Licenses Novel Payload Class From Cancer Research UK For The Development Of Next-Generation Antibody Drug Conjugates

September 26, 2017

·

3 min read

Glythera -Led Consortium Wins Industrial Biotechnology Catalyst Funding

July 27, 2015

·

6 min read

Glythera Unveils ADC Cysteine Linker Technology

October 24, 2014

·

5 min read

Glythera Limited Relocates to North East as Part of £2M Funding Round

June 21, 2012

·

5 min read